Is Growth Differentiation Factor 11 a Realistic Therapeutic for Aging-Dependent Muscle Defects?

Shavonn C Harper1, Andrew Brack1, Scott MacDonnell1

  • 1From the Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (S.C.H., S.R.H.); Eli and Edythe Broad Center of Stem Cell Research and Regeneration Medicine, Department of Orthopaedic Surgery, University of California, San Francisco (A.B.); Department of Cardiovascular Research (S.M.), and Department of Research Beyond Borders (M.F.), Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT (S.M., M.F.); Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder (B.B.O.); Department of Biology, Ursinus College, Collegeville, PA (B.A.B.); Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada (M.A.R.); and Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (M.A.R.).

Circulation Research
|April 2, 2016
PubMed
Summary

Elevating growth differentiation factor 11 (GDF11) in old animals may not rejuvenate muscles or reverse cardiac issues. New research suggests GDF11 may harm skeletal muscle repair and cause adverse effects, potentially worsening aging-related conditions.